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CHAPTER I. GENERALINTRODUCTION
Terrestrial plants andanimals represent biologicallyimportant
entities and have beenutilized to treat humandiseases since
antiquity.Studies of the secondarymetabolites of terrestrialplants
and animals were begunin the 1800's.' However,until the last
three decades of this century,there have beenincreasingly
intensive efforts towardexploring the marineenvironment for
useful biomedicinalagents.'Especially over the last decade,
advances in diving technologyhave opened up vast areasof
unexplored marine environmentsand habitatsto marine natural
product scientists.The marine environmentis an exceptional
reservoir of bioactivenatural products, many ofwhich exhibit
structural features not foundin terrestrial naturalproducts.In
addition, many marinecompounds have been found tobe useful as
biochemical tools for exploringcellular processes at themolecular
level.
The discovery andisolation of potentiallyuseful bioactive
natural products leads tothe next stage of drugdevelopment:
structural characterizationand analysis.The area of molecular
characterization has benefitedtremendously from advancesin
digital electronics andmodern analysis instrumentsof incredible2
power.In particular, nuclear magnetic resonancespectroscopy
(NMR) is able to completely define thethree-dimensional structure
of molecules with only microgramsof material.Currently, high-
field and microprobe NMR technologiesprovide a means to
investigate the structure of tracequantities of natural products.'"
Biomedical Potential of Marine NaturalProducts
The exploitation of resourcesfrom the sea has taken place over
thousands of years.For centuries the people of Chinaand Japan
have prepared an extract from theboiled fresh blades of the red
alga Digenea simplex to use as aremedy for intestinal parasite
infections of children."The consequent isolation and structure
determination of the biologically activeconstituent gave the
unusual amino acid, a-kainic acid(1, Figure I.1).12The origins of
the antiviral drug Ara-A (2),which is used in combination with
other agents to treat leukemia, canbe traced back to the
serendipitous isolation of the arabinosylnucleosides
spongothymidine (3) and spongouridine(4) from the sponge
Cryptotethia cryta.The observation of beach flies killedby contact
with the marine annelid Lumbriconereisheteropoda led to the
discovery of an unusual sulfurcontaining toxic amine, nereistoxin
(5) which served as a lead compoundfor the synthesis of a new
insecticide, PADEN (6).13.143
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Throughout the 1980s, biomedicalinvestigations of marine
natural products focused on ionchannel effectors and central
nervous systemmembrane-active toxins, anticancerand antiviral
agents, tumor promoters,and anti-inflammatoryagents.'
Stypoldione (7, Figure I. 2) , apotent fish toxin, wasisolated
from the tropical brownalgae Stypopdium zonale.It was found to
be cytotoxic by inhibitingmitotic spindle formationvia inhibition of
microtubule polymerization,the mechanism of actionfor several
clinically useful anticanceragents.16.
17Halomon (8) from a
Philippine collection of thered alga Portieria hornemanniihas been
selected by the NCI DecisionNetwork Committee forpreclinical drug
development due to its extremeselectivity to brain, renal andcolon
tumor cell lines."The deep-water spongeDercitus sp. collected in
the Bahamas yielded thenovel aminoacridine alkaloiddercitin (9),
which possesses in vitrocytotoxic activities in the lownanomolar
concentrationrange.19Cribrostatin 1 (10) fromdeep-blue
specimens of Cribrochaline sp.shows selective activityagainst all
nine human melanoma celllines in the NCI'spanel.'
Palytoxin (11, Figure I. 3) has notonly been found in Palythoa
soft corals but also inwide variety of otherorganisms,' such as the
seaweed Chondria armata,crabs belonging to be the genera
Demania and Lophozozyinus, atriggerfish Melichtys vidua, and a
file-fish Aluterascripta.22-24More recently, polytoxinanalogs have
been isolated from thedinoflagellate Ostreopsissiamensis, calling
into question the biogeneticorigin of palytoxin.25It stimulates
arachidonic acid metabolismand regulates the response to
epidermal growth factor byactivating a sodium pump in asignal7
transduction pathway using sodium as asecondary messenger.
These activities make palytoxin auseful tool for probing cellular
recognition processes!'
The sea hares are herbivorousopisthobranch molluscs that
concentrate and storeselected algal metabolites fromtheir diet.
Dolabella auricularia, collectedin the Indian Ocean, has beenthe
source of more than15 cytotoxic peptides, thedolastatins.The
most active metabolite,dolastatin 10 (12, Figure 1.2) is oneof the
most potent antineoplasticsubstances known.'Didemnin-B (13)
extracted from the Caribbeantunicate, Trididemnum solidum,
exhibits an impressive array ofin vivo antitumor,antiviral, and
immunosuppressant activities andbecame the first marine
compound to enter human cancerclinical trials as a purifiednatural
product.n. 28
Marine Toxins
Marine toxin research has become acrucial part of marine
natural products studies due totheir involvement in human
intoxication, animal poisoningsand economic impact brought onby
these types of incidents.In general, marine toxins arehighly
targeted to specific biomolecular receptorsand have unique
structural features not foundin terrestrial compounds.For
example, one of the best knowntoxins, tetradotoxin (14, Figure1.4),
isolated from the pufferfishand finally traced to symbioticbacteria
(e.g., Shewanella alga), togetherwith saxitoxin (15) produced by aHO
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number of dinoflagellate species (e.g., Alexandrium sppand
Gymnodinium catenatum) as well as some strains ofthe fresh water
cyano-bacterium Aphanizomenonflos-aquae,'"are involved
frequently in fatal poisoning due to blockingthe sodium channel in
excitable membranes.32-34Another class of shellfish toxins, well
known as diarrhetic shellfish poisons [e.g.,okadaic acid (16) found
in the dinoflagellate Prorocentrum lima35], have been shown to be a
completely new type of phosphataseinhibitor.36,
37Ciguatoxin (17),
a polyether compoundthat causes seafood poisoning in humansby
ingestion of coral reef fish that becometoxic through their diet was
found to be produced by the epiphyticdinoflagellate Gambierdiscus
toxicus.38Maitotoxin (18, Figure I. 5) with thelargest molecular
weight (3422Da) of any non-biopolymernatural product and its
extremely potent bioactivity, has attractedmuch attention in the
scientific community.Maitotoxin's lethality against mice (LD50 = 50
ng/ml) indicated that it might be the most potentnonproteineceous
toxin in nature."The total structure of maitotoxin hasrecently
been proposed on the basis of extensivespectroscopic analysis
including high-field multi-dimensional NMRmethods."
Along the Florida coast, the dinoflagellateGymnodinium breve
causes massive fishmortality.'Brevetoxin A (19, Figure I. 6) is
the most potent ichthyotoxin among thesuite of toxins produced by
the microalga (its lethality againstzebrafish is reportedly 3 ppb42'
43).These toxins have proved to be valuabletools as activators of
sodium channels."
As these previous studies show, many of themarine toxins
with unique structures and pharmacologicalproperties have been12
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found to be very useful tools for biological,medical, pharmacological
and ecological studie,'." as well asattractive targets for chemical
modification followed by structure-activityrelationship studies.',
as
$ioactive Natural Products FromMarine Cyanobacteria
The cyanobacteria, or blue-greenalgae, are prokaryotic
photosynthetic organisms which havebeen identified as a rich
source of unusualtoxins". 51 and biologically active lead
compounds.'An early survey of marinecyanobacteria crude
extracts showed 6% to becytotoxic to KB cancer cells withMICs < 30
ug/ml, 9% to possess antifungalactivity, and > 5% to possess
antiviral activity to Herpes simplex typeII."Reports of the potent
toxicity associated with cyanobacteriagrowing in nature suggest
that cyanobacteria serve aspromising sources of cytotoxic,
fungicidal, antiviral and antimicrobialactive compounds.5"4
Motuporin (20, Figure I.7), which is derived from symbiotic
cyanobacteria, was isolated from the spongeTheonella swinhoei.55
Microcystin-LR (21) is the most commonmicrocystin cyclic
heptapeptide from Microcystis, Anabaena,Oscillatoria, and Nostoc
species.It displays an LDso of 50 µg /m1in mice.'' 57From recent
reports, Microcystis aeruginosahas been shown to simultaneously
produce a series of depsipeptidescalled aeruginopepsins (i.e.
aeruginopepsin 917S-A, 22), which appear toenhance the toxic
effects of themicrocystins.5816
Tolypothrix, Scytonema, and Cylindrospermum species have
been shown to contain cytostatic and antimitotic metabolites called
sytophycins. Tolytoxin (23, Figure I. 7), as one member of them,
exerts a selective inhibitory effect on certainhuman tissue/tumor
types in comparative bioassays performed at the U. S.National
Cancer Institute."Westiellamide (24), a bistratamide-related cyclic
peptide isolated from Westiellopsis prolifica, was cytotoxic against
the KB and LoVo cell lines at 2 Tantazole B (25) from
Scytonema mirabile is cytotoxic to KB cells at doses ranging from
0.01 to 10 pig/m1,61 while tolyporphin (26) produced by Tolypothrix
ondosa potentiates the cytotoxicity of adriamycin or vinblastine in a
vinblastine-resistant tumor cell line (SK-VLB) at doses as low as1
4g/mi.62Cyanobacteria also appear to be a rich source of new
antiviral compounds.For example, the Nostoc sphaericum
metabolite, 6-cyano-5-methoxy-12-methylindolo[2,3-cdcarbazole
(27) displays anti-HSV-2 activity."
Two additional classes of potentially important marine natural
products were isolated from Caribbean collections of Lyngbya
majuscula.Microcolin A (28) suppresses the two-way murine
mixed lymphocyte reaction at low nanomolar concentrations."
Curacin A (29), a unique thiazoline-containing lipid isolated from a
Curacao collection of Lyngbya majuscula, is an exceptionally potent
antiproliferative agent that shows some selectivity for colon, renal,
and breast cancer-derived cell lines.'17
Description of Chapters
This thesis consists of a total offour chapters and an appendix.
Following this general introduction,chapter II describes the
discovery of a potent new toxicnatural product named kalkitoxin.
Determination of the chemical structureof kalkitoxin was made
possible through the extensiveinvestigation by NMR spectroscopy
including 2D-NMR at two different temperatures.Chapter II also
details the methods for the brineshrimp toxicity guided
fractionation and bioactivity evaluationof kalkitoxin.
The third chapter describes theisolation and structural
elucidation of two new malyngamidesfrom the Curacao Lyngbya
majuscula.The structure of these twomolecules were determined
by using 2D-NMR methodologytogether with comparisons of other
malyngamides.The stereochemistry of malyngamideJ was
investigated by using NMR andcircular dichroic spectroscopic
techniques.
Chapter IV give a conclusion aboutthis investigation of Curacao
Lyngbya majuscula and perspectiveof these three novel bioactive
metabolites.18
CHAPTER II
KALKITOXIN FROM THE CYANOBACIERIUMLYNGBYA MAJUSCULA
Abstract
Lyngbya majuscula, a chemically andbiologically rich strain of
cyanobacteria, has been intensivelyresearched for its biomedical
potential.Brine shrimp toxicity assay-guidedfractionation of an
organic extract of Lyngbya majusculafrom a Curacao collection led
to the isolation of a potentbrine shrimp toxic compound.The
structure of this new thiazolinecontaining lipid, named kalkitoxin,
was deduced fromextensive spectroscopic investigation.Other
biological properties of kalkitoxin such asichthyotoxicity and
molluscicidal activity have also beeninvestigated.19
Introduction
Cyanobacteria, or blue-green algae, are foundalmost
everywhere that light and water are available.In freshwater
environments, blooms of toxic cyanobacteria can poseserious
dangers for wildlife and livestock." Alarge number of interesting
metabolites have been isolated fromcyanobacteria.Their unique
structures and biological activitieshave received increasing
attention from chemists andpharmacologists."'
Most of the investigated cyanobacteria arefreshwater or
terrestrial in origin.Only a limited number of marine cyanobacteria
have been searched for secondarymetabolites.Nevertheless, there
are a number ofindications that cyanobacteria are important
players in the production of interestingcompounds that are found
widely in marine environments.From the brackish water species,
Nodularia spumigena, the cyclic pentapeptidenodularin (1, Figure
II.1) which had caused problems in the BalticSea and New Zealand,
was isolated.'This compound is closely related to microcystin(2),
a potent hepatotoxinand protein phosphatase 2 and 2A inhibitor
from the fresh-water cyanobacteriumMicrocystisaeruginosa.68
A marine strain of Nostoc linckia producedthe potent cytotoxin
borophycin (3), the structure of which wasdetermined by X-ray
crystallography.'Tjipanazole Al (4), a N-glycoside ofindolo-[2,3-
c]carbazole isolated from Tolypothrixtjipanasensis, exhibited
appreciable fungicidal activity intests against phytopathogenic
fungi." From an Australian Cylindrospemopsisraciborskii culture,20
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which was obtained following an outbreak ofhepatoenteritis on
Palm Island in northern Queensland, cylindrospermopsin(5), a
potent hepatotoxin, has beenisolated.'
of the most important cyanobacterialnatural products
have been isolated from Lyngbya majuscula, amarine filamentous
form. Lyngbyatoxin A (6, Figure 11.2),together with
debromoaplysiatoxin(7), were isolated from a toxic strain of
Lyngbya majuscula collected in Hawaii and shown tobe the cause of
the severe contact dermatitis known asswimmer's itch.'Both
classes of compound have played a significantrole in the study of
protein kinase C (PKC) due to their binding tothe phorbol ester
receptor on PKC.72."Majusculamide A (8), an unusual fatty acid
amide derivative, was reported from a deep waterLyngbya
majuscula."
Our investigation of marine algae foranticancer drug leads has
resulted in the identification of several structurallydiverse
cytotoxic metabolites from microalgal sources.Hormothamnin A
(9), isolated from the northern Puerto RicanHormothamnion
enteromorphoides, was found to be potentlyantimicrobial to
Bacillus subtilus and cytotoxic to several cancercell lines.'Isolated
from the Caribbean cyanobacterium Lyngbyamajuscula, barbamide
(10, Figure 11.3), a chlorinated metabolitewith molluscicidal
activity, together with antillatoxin (11) whichexhibits extremely
potent ichthyotoxicity, were reportedrecently:16a'Utilizing toxicity
to brine shrimp as a bioassay, aunique thiazoline containing lipid,
curacin A (12), was discovered from the organic extractof a
Curacao collection of Lyngbyamajuscula.'Curacin A is a potentOH
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antimitotic agent that inhibits microtubuleassembly and colchicine
binding to tubulin (Figure 11.3).78.79A Venezuelan collection of
Lyngbya majuscula yielded animmunosuppressive linear peptide
microcolin A (13),64 while a Curacaocollection provided microcolin C
(14).81These lipopeptides exhibited potentcytotoxic activity
against several cell lines in vitrosuch as A 549 (79% inhibition),
SW-480 (97% inhibition), and HMEC(90% inhibition) performed by
the Sandoz Corp.
Results and Discussion
Lyngbya majuscula from Playa Kalki,Curacao was collected at a
depth of 20 ft.It was preserved in isopropanoland stored at -20
°C.The organic extract was producedfrom the homogenized alga in
CH2C12/Me0H (2:1, v/v), allowed to soakaround 30 minutes, and
filtered through cheese cloth.The algal material was placed in fresh
solvent (CH2C12 /MeOH, 2:1 v/v),heated to a gentle boil up to 20
minutes, and filtered.This process was repeated two times.The
filtrate was partitioned betweenCH2C12 and water, and the organic
fraction was reduced in vacuo andstored in Et20 (4.32 g, dark green
oil).
The isopropyl alcohol preservedsample (1L) was filtered prior
to extraction.This alcohol was removed fromthe filtrate by
evaporation in vacuo and added tothe aqueous extract.The
CH2Cl2 /MeOH extracted algalresidue was soaked in Me0H/H20 (3:1,
v/v) overnight, filtered, and thealcohol was removed in vacuo. The25
aqueous extract waspartitioned between sec-butanoland water.
The sec-butanol fraction (0.6g, dark greenoil) was reduced in
vacuo and storedin Me0H (Figure 11.4).
This investigation focused on theorganic extract. Two-
dimensional TLC analysis (EtOAc /hexane1:1; CHC13/Me0H 9:1) of the
organic extract suggested the presenceof several UV-active
secondary metabolites.The crude extract was highlytoxic to brine
shrimp (100% killed at 10ggim1).82Hence, the brine shrimp
toxicity assay was utilized toguide each fractionation of this extract
(Figure 11.5).The first fractionation step utilizedgradient vacuum
chromatography (4%-40% EtOAC/hexane) togive seven fractions
after recombination.Among them, fraction C gave thehighest
toxicity against brine shrimp (100%killed at 1 µg /ml, Figure II.6a).
Further flash chromatography (4%-40%EtOAC/hexane) was applied
to fraction C to give atotal of ten fractions.Brine shrimp toxicity
assay II exhibited aselective toxicity in fraction C-4(Figure II.6b).
The continued fractionationmonitored with the brine shrimp
toxicity assay (column chromatography,40% EtOAC/hexane) led me
to focus on fractionC-4-G (Figure II.6c).The final purification was
performed by HPLC (40% EtOAC/hexane) toyield 12.8 mg of
compound 15, named kalkitoxin(Figure II.6d, Figure 11.7).
Kalkitoxin showed [a],), = +16° (c =0.07, CHC13). High resolution EIMS
(70 eV) gave a major [M]+ ion atm/z 366.2696 analyzing for
C21H381\120S (-0.8 mamu dev.). Theformula C211438N2OS indicated that
kalkitoxin possessed four degrees ofunsaturation.From "C NMR
analysis, two of these degrees weredue to double bonds, one due to
carbonyl group, and the remaining one to aring system.Organic extract
(4.32 g)
Lyngbya majuscula
(in 1 L)
1.partially defrost
2. filter off preservation alcohol
3. extract cold in 2:1 CH2Cl2 /MeOH
4. gently heat it in 2:1 CH2Cl2/MeOH
for 30 min, cool, filter
5. repeat #4 twice
residue I
soak in 3:1 Me0H/H20
overnight, then filter 1
aqueouslayer)
reduce at 40 °C,
partition with
sec-butanol i'
sec-butanol
i'
"Aqueousextract"
(0.66g)
H20
reduce
aqueous
partition
between
CH2Cl2 / H2O
add
organic solvent layer cJ2Cl2layer H20
(discard)
algal
material
filter particulates,
reduce on rotovap at 40°C
Figure 11.4 Extractionof Lyngbya majuscula.LKalkitoxin
(12.8 mg)
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Assay IV
Organic Extract of Lyngbya majuscula
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Figure 11.5Bioguided Fractionation of Kalkitoxin28
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Figure II.6bBrine Shrimp Assay IIfor Bioguided Isolation of
Kalkitoxin.29
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The structure elucidation of compound 15 wasmostly based on
extensive 1D and 2D NMR experiments. A complicationof this
structure elucidation was that at room temperature(298K) many of
NMR signal were twinned in a 3:2 ratio (inD6-DMSO, Figure 11.9).
That was due to the presence of two slowlyinterconverting amide
conformers (Figure II.10).The fact that these twinned proton peaks
changed ratios in different NMR solvents confirmedthat they arose
from two conformations of this molecule (tableII.1).However, at
high temperature (340K) these peaks coalesced tosinglets (Figure
II.11).While the high temperature NMR experimentsprovided
valuable information for this structureelucidation, there was a
complicating factor in that at the high temperature someof '3C NMR
signals were missing and some '11-'3C correlations werelost (Figure
11.12-13).Therefore, the structure elucidation was based onthe
combination of the two sets of NMR experiments at298K and 340K.
Data from 'H -'H COSY, HMQC, DEPT and'H NMR decoupling
experiments (Figure 11.14-17) allowed deduction ofsix partial
structures (a-f, Figure 11.8) for compound15.Partial structure b
contained a tertiary amide group which caused the two
conformations in this molecule.Partial structure f possessed a
terminal olefin adjacent to a thiazoline ring.This partial structure
assignment was also based on analysis of EIMSdata and
comparisons of '3C NMR chemical shifts withmodel compounds.'' 85,
86 Partial structure e possessed a CH3-CH-CH2 groupingwhile partial
structure a contained a high fieldC4 group with two methyls.The
partial structure c had a high field C4 groupwith one methyl group.a
2
14 15
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1
Figure 11.7 The Overall PlanarStructure of Kalkitoxin.
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Figure 11.8Six Partial Structures of Kalkitoxin.32
HMBC data were used to connect these six partial structures to
give the full structural assignment of kalkitoxin (Figure11.18-19).
Notably, the proton at 54.90 in partial structure f and the
methylene protons at 62.23 and 62.45 in partial structure e were
both correlated to the quaternary carbon at 6168 of the thiazoline
ring.Similarly, partial structures b and c were readily connected
by observing long range coupling between the methyl protons
62.95/2.80 (at 298K) of amide b and the methylene carbon
647/44.8 of c as well as the carbonyl of the amide at 8174.8 andthe
methylene protons at 63.32 of c.In partial structure d, the
methylene protons at 61.10 showed clear correlations to the
methine carbon 636.7 of partial structure e and the methine at
627.5 of partial structure c. Table 11.2 displays '11 and13C NMR data
and coupling constants of kalkitoxin.
Kalkitoxin was found to possess highly potent brine shrimp
toxicity (LC50 = 28 ng/ml, Figure 11.20).This rapid in-house screen
has been shown to have a good correlation (p = 0.036) with the9KB
cytotoxicity assay.
88,89Also, kalkitoxin displayed modest
molluscicidal activity to Biomphalaria glambrata (LC100 = 22 µg /ml,
Figure II.21).84 This freshwater mollusc is an intermediate hostfor
three species of parasitic trematode blood flukes (shistosomes).
Over 200 million people in over 75 countries are infectedwith
schistosomiasis(bilharzia).87Chronic infection may result in
disturbances of the central nervous system, liver fibrosis, portal
hypertension, and possibly liver cancer.The difficulty and costs2
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Figure 11.911-1 NMR Of Kalkitoxin InD6-DMSO At Room Temperature298K.34
Table II.1The ratio of N-methyl group resonances in the'H NMR
spectra of the two conformers of kalkitoxin invarious NMR solvents
solvent chemical shift ratio
CDC13 2.95/2.90 1.27:1
C6D6 2.79/2.43 0.5: 1
D6-acetone 3.05/2.85 1.58:1
D4-Methanol 2.95/2.80 1.2 :1
D6-DMS0 2.95/2.80 1.5: 1
D4-Me0D/CDC13 3.06/2.94 1.22: 1
1:1
* at room temperature 298K.
0-
CH3
2.95
(in D6 -DMSO)
2.80
H3C.
0-
FigureII.10
Two slowly intercovertingtert-amide isomers
present at room temperature 298K.5
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Figure 11.191H and 13C NMR Assignment of Kalkitoxin (298K).44
Table 11.2 and "C NMR Data* of Kalkitoxin Isolated From
Lyngbya majuscula
C-atom "C (D6 -DMSO)
8
(D6-DMS0)
8(mult, J in Hz)
1 114.6 5.25 d (17.3)
5.10 d (10.6)
2 137.4 5.95 ddd (17.3, 10.6,6.2)
3 77.6 44.90 m
4 37.8 3.46 dd (10.8, 8.7)
3.03 dd (11.0, 7.9)
5 168.0
6 37.5 2.23 bdd (9.0, 14.5)
2.45 m
7 36.7 1.84 m
8 33.4 11.57 m
9 39.3 1.10 m
10 27.5 1.45 m
1 1 34.9 1.45 m
1.25 m
12 47/44.8 3.32 dd (5.6, 12.8)
1 3 19.0 0.87 s
14 16.0 0.85 s
15 16.0 0.83 s
16 34.7/33.0 2.97/2.80s
1' 174.8
2' 36.1 2.61 dd (6.7, 13.4)
3' 26.8 1.25 m
1.57 m
4' 11.7 0.84 d
5' 17.1/17.7 0.97 d (6.9)
* Data reported at room temperature 298K.120%
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40%
20%
0%
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Figure 11.20 Pure Kalkitoxin in Brine Shrimp Toxicity Assay.
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Figure 11.21Molluscicidal Activity of Kalkitoxin.
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Figure 11.22Ichthyotoxic Effects of Kalkitoxin.
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involved in treating these large groups of people in remote
impoverished areas has prompted a concerted effort by the World
Health Organization (W.H.O.) to look for new means of preventing
infection by controlling the snail vector.
Kalkitoxin showed extremely potent ichthyotoxicity to the
goldfish (LC50 = 5 ng/ml, Figure 11.22)."This is almost the same
potency as the well known and highly potent ichthyotoxic
metabolite, brevetoin A produced by G. breve (although tested
against different fish).
42,43As has occurred in the past, insect
antifeedants, antitumor agents, plant growth inhibitors, and
insecticides have been isolated from ichthyotoxic plants."These
biological features of kalkitoxin suggest possible ecological
interactions and inspire further investigation.47
Biosynthetically, kalkitoxin may derive from an acetyl CoA
joined with a decarboxylated cysteine residue and a malonyl CoA to
form a thiazoline ring attached with a terminal olefin.The middle
polyketide chain of kalkitoxin may derive from the consequent
condensations of methyl malonyl CoA, SAM and acetyl CoA.The
terminal C5 chain including the nitrogen of the amide is possibly
from a decarboxylated isoleucine.
Unfortunately, this research was not able to solve the
stereochemistry of kalkitoxin due to the limited amount of sample.
Experimental Methods
General Methods.Ultraviolet spectra were recorded on a
Hewlett Packard 8452A diode array spectrophotometer, and
infrared spectra (IR) were recorded on a Nicolet 510P-RHS spectro-
photometer.Nuclear magnetic resonance (NMR) spectra were
recorded on a Bruker AM 400 NMR spectrometer.All NMR
chemical shifts are reported relative to an internal
tetramethylsilane (TMS) standard and '3C spectra referenced to the
center line D6 -DMSO at 39.25 ppm. Low resolution mass spectra
(LRMS) were obtained on a Varian MAT CH7 spectrometer, while
high resolution mass spectra (HRMS) were obtained on a Kratos MS
50 TC.High performance liquid chromatography (HPLC) was done
using a M-6000 pump, U6K injector and either R 401 differential
refractometer or a lambda-Max 480 lc spectrophotometer.TLC-
grade (10-40 ilm) silica gel was used for vacuum chromatography,48
Kieselgel 60 silica (40-63 1.tm) was used for flash chromatography,
and Merck aluminum-backed TLC sheets (silica gel 60 F254) were
used for thin layer chromatography.All solvents were distilled
from glass prior to use.
This Lyngbya majuscula was collected from Playa Kalki,
Curacao (20 ft underwater) on 11 August 1994 and preserved in
isopropyl alcohol and frozen until workup.The defrosted alga was
homogenized in CH2C12 /MeOH (2:1, v/v).The algal residue was
repetitively extracted with CH2C12 /MeOH (2:1, v/v) twice. The
mixture was filtered and the solvents removed under vacuum to
yield a residue which was partitioned between CH2C12 and H2O. The
CH2C12 solution was collected. A total of 4.32 g dark-green oily crude
organic extract was obtained.
The bioguided fractionation of the crude extract was obtained
by silica gel vacuum chromatography, flash chromatography, and
column chromatography.Finally, a normal phase HPLC was applied
to give kalkitoxin (15 12.8 mg), as a light yellow oil (Figure 11.7).
The 'H and '3C NMR spectra of kalkitoxin show very clean base
lines and The HPLC of kalkitoxin displayed a symmetric peak. These
suggested kalkitoxin great purity (> 95%)
Kalkitoxin(1 5).IR (CHCI3 v 2961, 2928, 2880, 1643, 1464,
1086, 1410, 1380 cm'; UV (MeOH) Xmax 250 nm (E = 2600);Optical
rotation [a]p = +16° (c = 0.07, CHC13); HR EIMS (70 eV) m/z obs. [M]+
366.2696 (16, -0.8 mmu dev.) C21H381\120S, [M-CH3]+ 351.2472 (5.5,
0.2 mmu dev), [M-C2H3]+ 339.2465 (5.7, -0.5 mmu dev), [M-CH2CH3]+
337.2294 (2.5, -1.9 mmu dev), 281.2591 (7, -0.2 mmu dev), [M-
05H9O]+ 281.2049 (3.9, -0.2 mmu dev), 265.2271 (2.4, -0.8 mmu49
dev), [M-C61-18NS]+ 240.2329 (25, 0.2 mmu dev), [M-C,H14NO]+
238.1639 (5, 1.0 mmu dev), [M-C8H16NO]+ 224.1470 (1.9, -0.3 mmu
dev), 212.9960 (2, 0.9 mmu dev), 195.1860 (2.3, -0.1 mmu dev),
[M-C111122N0]+ 182.1003 (4.4, -0.05 mmu dev), 156.1750 (5.2, -0.2
mmu dev), [M-C13H26NO]+ 154.0683 (100, -0.8 mmu dev), 149.0244
(1.5, 0.5 mmu dev), 142.1237 (2, 0.5 mmu dev), 140.0531 (2.6, -0.3
mmu dev), 129.1155 (3.8, 0.1 mmu dev), [C6H9NS]+ 127.0459 (26,
0.3 mmu dev);'I-1 NMR and "C NMR data see Table 11.2.
Brine Shrimp Bioassay.The brine shrimp toxicity assay was
used to analyze levels of toxicity at different concentrations of
sample and this assay was utilized to guide fractionation of the
sample.Brine shrimp eggs were incubated in Instant Ocean® water
at 28 °C for 24 hours before the assay to allow the eggs to hatch and
mature. Approximately 90% of the eggs usually hatch after this
incubation period.'A shallow rectangular dish filled with artificial
seawater (Instant Ocean®, Aquarium Systems, Inc.) containing a
plastic divider with several 2 mm holes was used to separate the
unhatched eggs from the nauphali.The eggs were sprinkled into
one compartment that was kept in the dark for the incubation
period.After 24 hours, the phototropic nauphali were collected
from the lighted compartment.Approximately 15 shrimp were
added to each vial containing different concentrations of sample in
4.5 ml artificial seawater.Appropriate solvent controls were done
in duplicate.The brine shrimp were added to each vial using a long
stem pipette.After 24 hours at 28 °C, the shrimp were counted
using a dissecting light microscope.The percentage of dead shrimp50
relative to the total number of shrimp was recorded for LC
measurement.
Ichthyotoxicity Assay. A single goldfish Carassius auratus was
added into a 50 ml beaker containing 40 ml of distilled H2O.The
sample was dissolved in 40 gl EtOH. In order to get an even solution
of the test compound, a microliter syringe was used to add the
sample solution at different water levels.The fish was observed for
a one hour period. End points were established asdeath (lack of
breathing) for LC measurement.
Molluscicidal Assay. The sample was dissolved in 40 tl EtOH
and diluted to 20 ml with distilled water to make several different
concentrations.Two Biomphalaria glambrata were placed in each
beaker and the beakers covered with glass plate for the duration of
the assay.The condition of the snails was evaluated after 24 hours.
Snail were considered dead when no heart beat could be observed
upon microscopic examination.Minimum lethal doses required to
kill the snails (LC100) were recorded.51
CHAPTER III
TWO NEW MALYNGAMIDES PROM THECYANOBACTERIUM LYNGBYA
MAJUSCULA
Abstract
Two new secondary metabolites,malyngamide J and
malyngamide L, have been isolated from aCuracao collection of the
cyanobacterium Lyngbya majuscula.The structure elucidation of
these new compounds was accomplishedby analysis of 1H NMR, "C
NMR and ID NMR, along with comparisonswith known natural
products.Stereochemistry and biological properties havebeen
investigated.52
Introduction
Cyanobacteria have been a source ofdiverse types of
secondary metabolites.Fatty acids are one of the most common
compositions in cyanobacteria, which arenormally present as C14 to
C18 components.Malyngic acid, 9(S), 12(R), 13(S)-
trihydroxyoctadeca-1 0(E),15(Z)-dienoicacid (16, Figure III.1) is a
major fatty acid that occurs inboth shallow-water and deep-water
varieties of Lyngbyamajuscula,91 while 9-methoxy-9-
methylhexadeca-4(E),8(E)-dienoic acid (17)is present in moderate
amounts in the deep-waterLyngbya majuscula."
In contrast to the situationin eukaryotic algae, nitrogen.
containing secondary metabolites are commonin cyanobacteria.
Shallow-water varieties of Lyngbyamajuscula contain amides of the
fatty acid 7(S)-methoxytetradec-4(E)-enoicacid (18), which in free
form displayed antimicrobialactivity to the gram positivebacteria
Staphylococcus aureus and Bacillussubtilus.On the other hand,
deep-water collections of Lyngbyamajuscula provided amides of 7-
methoxy-9-methylhexadec-4(E)-enoic acid(19)."
Malyngamide A (20) and malyngamideB (21) are two such amides
of 7(S)-methoxytetradec-4(E)-enoicacid (18), which have been
found in several shallow-watervarieties of Lyngbya majuscula
from Hawaii.9"Their structures were determinedby NMR
analysis and chemical degradationstudies.Malyngamide C (22), a
chlorine-containing amide of7(S)-methoxytetradec-4(E)-enoic acid,
was isolated from ashallow-water Lyngbya majusculafound on the53
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Figure III.1 Secondary Metabolitesfrom Different Varieties of
L. majuscula.54
reefs of Fanning Island in the Line Islands.' The complete
structure of 22, including absolute stereochemistry, was
determined by spectral and chemical studies.From a deep-water
collection of Lyngbya majuscula found on the pinnacles inEniwetok
lagoon, malyngamides D (23, Figure 111.2) and E (24), twoclosely
related amides of 7(S)-methoxy-9-methylhexadec-4(E)-enoicacid
(19) have been found.Detailed spectral analysis and chemical
degradation studies defined the structures and the ring
stereochemistry."
Malyngamide F (25) was reported from shallow water
collections of a Caribbean Lyngbya majuscula.This secondary
metabolite showed mild cytotoxicity (ID50 <30 µg /ml) againstKB
cells in tissue culture.The structure elucidation was based on 2D
NMR data and chemical interconversion.97Malyngamide G (26) was
isolated from a cyanobacterium epiphyte on the brown
mediterranean alga Cystoseira crinita.98Guided by ichthyotoxicity
against goldfish, malyngamide I-1(27) was isolated from another
Caribbean L. majuscula.The structure and the absolute
stereochemistry of the cyclohexenone moiety was elucidated by
spectroscopic analysis and exciton chirality in the circulardichroism
spectrum.99The latest report of malyngamides was of malyngamide
I (28), isolated from a Okinawan shallow water collectionof
Lyngbya majuscula.This compound showed moderate toxicity
towards brine shrimp (LD50 ca. 35 µg /m1) and goldfish (LD50 <10
µg/m1)."°55
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Figure 111.2 Structures of VariousMalyngamides from
L. majuscula.56
Results and Discussion
For this work, a collection of Lyngbyamajuscula was made
from Playa Kalki, Curacao in about20 ft of water.The sample was
preserved in isopropanol and stored at-20 °C.The organic extract
was obtained fromthe homogenized alga by soakingin CH2C12 /MeOH
(2:1, v/v) for 30 minutesfollowed by filtration through cheese
cloth.The algal material was placed infresh solvent (CH2C12/Me011,
2:1 v/v), heated to a gentle boilfor 20 minutes, and filtered.This
process was repeatedtwice.The filtrate was partitionedbetween
CH2C12 and water, and the organicfraction was reduced in vacuo and
stored in Et20 (4.32 g, dark greenoil).
The isopropyl alcohol preservedsample (1L) was filtered prior
to extraction.This alcohol was removed byevaporation in vacuo
and the residue was added tothe aqueous extract.The
CH2C12 /MeOH extracted algalresidue was soaked in Me0H/H20(3:1,
v/v) overnight, filtered, and thealcohol was removed in vacuo.The
"aqueous extract" was partitionedbetween sec-butanol and water.
The sec-butanol fraction (0.68 g,dark green oil) was reduced in
vacuo and storedin Me0H (Figure 11.4).
Two-dimensional TLC analysis of theorganic extract suggested
the presence of several UV-activecompounds.The fractionation
utilized gradient vacuumchromatography (EtOAc /hexane, 4 %-
100 %), gradient flashchromatography (Me0H/CHC13, 0%-2%),RP C-
18 plug chromatography (MeOH/H20, 80%-100%) and HPLC (Alltech,
Lichrosorb Diol column 10u,Me0H/Et0Ac/hexane 1:3:16) to yield a
colorless lipid (29). This was shown tobe a new member of the57
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Figure 111.3The Isolation of Malyngamide J(29).58
malyngamide family, and was therefore named malyngamideJ
(Figure 111.3).Another less polar fraction was subjected tosilica gel
column chromatography (EtOAc /hexane, 85%),gradient flash
chromatography (Me0H/ CHC13, 0.1%-10%v/v) and HPLC (Alltech,
Lichrosorb Diol column 10u, Me0H/Et0Ac/hexane1.5:9:120 v/v) to
give a light-yellow oil (30, malyngamide L,Figure 111.4).
Compound 29 showed optical rotation [43 +64°(c = 0.15,
CHC13).High resolution FAB MS (positive ion,3-nitrobenzyl alcohol)
gave a major [M+H]+ion at m/z 608.3798 (0.0 mmu dev.) which was
consistent with a molecular formula ofC33H53N09.This molecular
formula indicated that compound 29 possessedeight degrees of
unsaturation.Analysis of UV (MeOH, Xma, 240 nm c =5600), 111 NMR
and "C NMR data (Table III.1) revealed the presenceof three
double bonds, an amide carbonyl group, an a,0-unsaturated
carbonyl, and three rings.
By using COSY and HETCOR spectral data (Figure 111.5),
several distinct spin systems could beassembled (Figure 111.6).
Fragment a possessed a 7-methoxytetradec-4(E)-enonatemoiety,
which is a common feature of malyngamides.The partial structure
b placed two consecutive methylene groupscontiguous to an amide
N atom by observation of HMBC correlationsbetween the methylene
protons Ha,b-1 (83.43 , 83.37) andthe carbonyl carbon C-1' (8172.7).
The deshielded methylene singlets Ha,,,-4(85.22, 85.28) showed no
correlation by '11-11-1 COSY to any other groupand suggested a
terminal olefin with a quaternary carbon inpartial structure c.
111-'14 COSY correlations gave the partial structure dwith a59
Extract of Lyngbya majuscula from Curacao
(4.32g)
EtOAc / Hexane 4%--100% Gradient Vacuum Chromatography
4% 25% 25% 50% 50% 75% 100%
(100 mg)
Column Chromatography
EtOAc / Hexane 85%
4
Me0H / CHC13 0.1% -- 10%
1 10
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Figure 111.4The Isolation of Malyngamide L (30).60
deshielded methylene contiguous to four consecutive deshielded
methines.The more deshielded methine C-12 (1H 54.48,"C 5103) at
the end of this chain suggested an acetal carbon.In partial
structure e, a long range coupling wasclearly observed by 11-1-111
COSY between the deshielded methyl 51.88 (C-11) andthe olefin
proton 5 6.42 (H-8). This placed the methyl group onthe quaternary
carbon (C-7) of the olefin, next to which were twosequential
deshielded methine groups 54.68 (I1-9), 53.70 (H-10).The "C
chemical shift of 563.8 for the C-10 methineCH 53.70) and a
quaternary carbon at 562.3 (C-5) suggestedthe presence of an
epoxide ring.The HMBC correlation between the 11-10 proton
(53.70) and the C-5 quaternary carbon (562.3) confirmedthis
assignment.
These partial structures were connected byinterpretation of long-
range correlations observedin the HMBC spectrum (Figure 111.7).
The correlation cross-peak observed from Hab-1 toC-1' secured the
amide linkage between partial structures a and b.The correlation
seen from 11.,b-4 to C-5 andC-2 confirmed the connections between
partial structure c, b and e of the cyclohexenone.The correlations
between Ham-16 and C-12 completed asix-membered heterocyclic
ring.The correlation observed from H-12 to C-9 andfrom H-9 to
C-12 confirmed the linkage between the cyclohexenoneand
dimethylated pentose sugar. The correlations seenfrom the H3-17
methoxyl group (53.6) to C-13 at 582.8 and from theH3-18
methoxyl to C-15 (578.9) placed these methoxyl groups onthe
methine carbons C-13 and C-15.From these data, a full assignment4'5'
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17
12 18A
10 13
16b 11
MAO 8
9'
HO
14
0
43.1
.5
_1.0
9
_1.5
0 2.0
O
0 2.5
O
3.0
0
3.5
-4.0
-4.5 O
5.0
A 09 5.5
0 s-00.
_6.0
0 0 _6.5
6.56.05.55.0 4.54.0
PPM
3.53.02.52.0 1.5 1.0 .5
PPM
Figure 111.5 1H-1H COSY of MalyngamideJ (29).62
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Figure 111.6 Partial Structures ofMalyngamide J
by 1H-1H COSY and HETCOR.63
Table 11.1'H,'3C and HMBC NMR Data Of Malyngamide J (29)
C-atom '3C (CDC13)
8 for 1
'H (CDC13) for 1
8 muti J in Hz
HMBC
1 37.5 3.37 m 1', 3, 2
3.43 m
2 33.0 2.44 m 3, 4, 5
2.35 m
3 139.9 --
4 117.6 5.22 s 5,2
5.28 s 5, 2, 3
5 62.3
6 194.2
7 136.1
8 136.9 6.42 bs 11, 10
9 70.4 4.68 bd (4.4) 7, 12, 5, 10
10 63.8 3.7 bs 8, 5, 9
11 16.5 1.88 s 6, 7, 8
12 103 4.48 d (7.4) 9, 17
13 82.8 3.02 dd (9.2, 7.4) 17, 14, 12
14 75.5 3.53 dd (10.6, 8.9) 13, 15
15 78.9 3.25 dddm (5.0, 9.1,8.9)18, 14
16 63.4 3.15 bdd (8.9, 11.5) 14, 15, 12
4.04 dd (5.0, 11.5) 14, 12
17 58.9 3.6 s 13
18 61.0 3.5 s 15, 14
1' 172.7 -
2' 36.8 2.28 m 1', 3' 4'
3' 28.9 2.35 m 4' 5'
4' 131.2 5.48 m 3', 6'
5' 127.6 5.48 m 3', 6'
6' 36.6 2.18 m 5', 7'
7' 81.0 3.15 m 6', 15'
8' 33.4 1.43 m
9' 32.0 1.28 m
10' 28.9 1.28 m
11' 29.5 1.28 m
12' 30.0 1.28 m
13' 22.9 1.28 m
14' 14.3 0.89 t (6.7) 13', 12'
15' 56.7 3.32 s 7'
NH 6.07 m 1'
OH 2.78 bs 14, 15, 1364
14'
1.28 1.28 1.28
0.89 1.28 1.28 1.43
3.32
OCH3
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Figure 111.7 The Structureof Malyngamide J (29) with1H and
13CNMR Assignments by HMBCCorrelations.65
Table 111.2'1-1 and 13C NMR Date of Malyngamide L (30) from L. majuscula
C-atom 13C (CDC13)
5
1H (CDC13)
5 muti, J in Hz
1 44.0 3.94 d (6.1)
2 136.7
3 119.7 6.2 bs
4 136.5
5 198.6
6 38.6 2.54 ddd (6.5, 13.5)
7 22.8 2.08 ddd (6.5, 13.2, 10.3)
8 26.3 2.50 ddd (10.2, 4.3)
9 151.5 6.95 t (4.1)
1' 172.5
2' 36.6 2.24 dd (5.8, 7.5)
3' 29.5 2.32 m
4' 130.9 5.47 m
5' 127.9 5.47 m
6' 36.6 2.20 m
7' 80.9 3.15 dddd (5.8, 11.4)
8' 33.6 1.43 m
9' 32.0 1.28 m
1C' 25.5 1.28 m
11' 29.9 1.28 m
12' 30.0 1.28 m
13' 22.8 1.28 m
14' 14.3 0.88 mt
15' 56.7 3.34
NH 6.10 m
of the planar structure of malyngamide J (29) wasestablished.
This is the first malyngamide-type natural product tobe found
containing a sugar in the molecule.
The relative stereochemistry of the dimethoxylated pentose
sugar in compound 29 wasestablished through the analysis of the
proton coupling constants and nOeobservations.The coupling
constant between H-13 (53.02) andH-14 (53.53) was 9.2 Hz which
indicated these two protons were diaxial (FigureIII.10).Similarly,
the coupling constants 8.9 Hz between H-15and H-16a (53.15);10.6
Hz between H-14 and H-15 (53.25) gave theirdiaxial orientation,66
while J15,16b = 5.0 Hz suggested that H-16b (84.04) is in the equatorial
orientation.A cross peak between H-13 and H-15 in the NOESY
confirmed their axial orientations.Although the observed coupling
constant between H-12 and H-13 was 7.4 Hz, a nOecorrelation
between H-16a, H-14 and H-12 (84.48) provided unambiguous
evidence that H-12 was axial. Thus, an a-dimethoxylated xylose
structure can be assigned.The absolute stereochemistry of the
sugar was not investigated, but may be Dbased on the previously
isolation of D-xylose from L. majuscula.
A small coupling constant between H-9 and H-10 (1.7 Hz)
required a dihedral angle between these protons to be around 60 °-
70°In combination with dihedral angle calculations from molecular
modeling (Chem3D-Plus), two of the stereomeric models (A and B,
Figure III.11) with dihedral angle 65° and 71° between 11-9 and H-
10 were best matched to the coupling constants based on Karplus's
equations.Thus, a trans relationship between H-9 and H-10 was
established.
The absolute stereochemistry of the epoxycyclohexenone ring
was determined by the observationof nOe between H-10 and H-4a,
H-9 combined with the CD analysis.'Both diastereomers (A' and
B', Figure 111.11) could reasonably display nOe between H-10 and
H-4a. The negative first Cotton effect (MeOH Aa247 max = -12.5) in
the CD spectrum can only be explained by conformation B', thus
establishing the absolute stereochemistry of C-9, C-10 and C-5 to be
R, S and S,respectively.Figure 111.12 shows the structures with
stereochemistry of malyngamide J (29).Dimethoxylated pentose ring of malyngamideJ (29)
3.6
H3co3.02
3.53
HO
2.78
0A
4.48
12O
3.25
OCH3
3.50
Coupling constants
3.15
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67
Figure Ill.10 Stereochemistryof Dimethoxylated Xylose Residue
in Malyngamide J (29).68
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Figure III.11Proposed CD and NOE of TwoMalyngamide J
Configurations.69
Compound 30 showed optical rotation [cc]D = -8.4° (c = 0.28,
CHC13). HRFAB MS (positive ion, 3-nitrobenzyl alcohol) gave a
[M+H]+ ion at m/z 424.2618 (0.0 mmu dev.) which was consistent
with the molecular formula C24H38NO3C1.This molecular formula
indicated six degrees of unsaturation.Examination of the UV (?max
223 nm, E = 8900), and "C NMR indicated the presence of an a, (3-
unsaturated carbonyl (8198.6), an amide carbonyl (8172.5) and six
olefinic carbons forming three double bonds (Table 111.2).Hence,
this compound was monocyclic.Furthermore, the 'H NMR spectrum
showed characteristics for a methoxylated fatty acid, a common
feature of malyngamides.Analysis of the 'H -'H COSY (Figure 111.8)
and 'I-1-13C HETCOR data and comparison with the spectral data of
malyngamide F (25)' gave a full structural assignment of
compound 30 (Figure 111.9).
The previous studies of malyngamides from L. majuscula have
shown that the stereochemistry of malyngamides at C-7' are always
of th S configuration."From the same extract, the known
metabolite malyngamide H (27) was isolated," which also contains
a S configuration at C-7'.Biosynthetic considerations suggest that
the 7-methoxytetradec-4-enoate moiety in malyngamide J (29) and
malyngamide L (30) have the same S configuration at position C-7'.
Malyngamide J showed brine shrimp toxicity with LC50 = 18
gg/m1 (ca.) and ichthyotoxicity with LC50 = 40 µg /ml, while
malyngamide L showed brine shrimp toxicity with LC50 = 6 µg /m1
and ichthyotoxicity with LC50 = 7 µg /ml.14'
I'
7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5 1.0 .5 0 !O
PPM
PPM
Figure 111.81H-1H COSY of Malyngmide L (30).
4.0
5.0
6.0
7.913' 11' 9'
14'
0.88
14.3
12' 10'
15'
3.34
8
22.829.9 32.0
30.025.533.6
56.7
OCH3
80.9
127.929.5
36.6N....
130.92.24
13C NMR
0
172.5 136.7
N 3.94
H
119.7
0
198.6
38.6
CI26.3
71
22.8
Figure 111.9 The Structureof Malyngamide L (30) with1H and
13CData.ders
(:)1573
Experimental
General Methods.Ultraviolet spectra were recorded on a
Hewlett Packard 8452A diode arrayspectrophotometer, and
infrared spectra (IR) were recorded on aNicolet 510P-RHS
spectrophotometer.Nuclear magnetic resonance (NMR) spectra
were recorded oneither Bruker AM 400 or Bruker AM 300 NMR
spectrometer.AllNMR chemical shifts are reported relative to
an internaltetramethylsilane (TMS) standard and"C spectra
referenced to the center line CDC13 at 77.25 ppm.CD measurements
were obtained on a Jasco41A spectropolarimeter.Low resolution
mass spectra (LRMS) wereobtained on a Varian MAT CH7
spectrometer, while high resolution massspectra (HRMS were
obtained on a Kratos MS 50 TC. Highperformance liquid
chromatography (HPLC) was performed using aM-6000 pump, U6K
injector and either R 401 differentialrefractometer or a lambda-
Max 480 lc spectrophotometer.TLC-grade (10-40 gm) silica gel was
used for vacuum chromatography andKieselgel 60 silica (40-63 gm)
was used for flashchromatography, and Merck aluminum-backed
TLC sheets (silica gel 60 F254) were usedfor thin layer
chromatography. All solvents were distilledfrom glass prior to use.
Isolation of Malyngamide J (2 9).The fractionation of the crude
extract was achieved by silicagel vacuum chromatography using a
stepwise gradient from 4% to 100% (v/v)EtOAc in hexane (Figure
111.3).Two-dimensional TLC (EtOAc /hexane 1:1; CHC13/MeOH9:1)
suggested the presence of severalUV-active secondary metabolites
in fraction E, and its 'H NMR spectrumshowed interesting structural74
features.Further fractionation was applied by gradientflash
chromatography (MeOH /CHC13, 0%-2%) andcontinued with
reversed-phase RP C-18 chromatography to remove mostof the
pigments.The final purification was completed byHPLC (10-p.m
Phenomenex Maxial Diol column,Me0H/Et0Ac/hexane 1/3/16) to
yield malyngamide J (29, 14.5 mg,Figure 111.3).
Isolation of Malyngamide L (3 0).The fractionation of the
crude extract was followed by silica gel vacuumchromatography
(EtOAc/hexane, 4%-100%, v/v).Two-dimensional TLC
(EtOAc /hexane 1:1; CHC13/MeOH 9:1)suggested the presence of
several UV-active compounds in fractionD (Figure 111.4).Further
fractionation was provided by silica gelchromatography (85%
EtOAc /hexane) followed by gradient flashchromatography
(MeOH /CHC13, 0%-10%). The natural product wasthen isolated by
using HPLC (10-pm Phenomenex MaxailDiol column,
Me0H/Et0Ac/hexane 1.5/9/120) to yield a UV-activenatural
product, named malyngamide L(30, 6.6 mg,Figure 111.4).
Malyngamide J (2 9). UV (MeOH) 'max 240 nm(E = 5600);
optical rotation [a]E, = +64° (c = 0.15,CHC13); CD (MeOH): DE = -12.5,
+9.2 (Xmax 247, 217 nm); HR FABMS(positive ion, 3-nitrobenzyl
alcohol) in/z obs. [M+H]+ 608.3798 (C33H54N09,0.0 mmu dev.); LR
FABMS nilz obs. 608 (28), 448 (100), 416(26), 192 (17), 175 (25),
163 (15), 136 (13), 101 (24), 95(13), 87 (24), 81 (26), 75 (27), 69
(42), 59 (12), 55 (31), 45 (33);'11 NMR and 13C NMR data see Table75
Malyngamide L (3 0). UV (MeOH) Xmax 223 nm (c = 8900);
optical rotation [oc]D = -8.4° (c = 0.28, CHC13); HR FABMS(positive
ion, 3-nitrobenzyl alcohol) m/z obs. [M+H]+ 424.2618(C24H39NO3C1,
0.0 mmu dev.); LR FABMS m/z obs. 424 (78),426 (32), 394 (20),
392 (57),388(8),307(17), 289 (15), 281 (14),220(15),186(10),
171(18),169(51),154(100), 150 (17), 138(30),136(82),133(10);
NMR and "C NMR data see Table 111.2.
Brine Shrimp Bioassay.See Chapter II. experimental.
Ichthyotoxicity Assay.See Chapter II. experimental.76
CHAPTER IV. CONCLUSION
Lyngbya majuscula has been recognized as achemically and
biologically rich strain.This investigation gave a good
representation showing the diversityof organic molecules produced
by Lyngbya majuscula. From asingle collection at Playa Kalki,
Curacao (11 August 1994), we haveisolated three novel bioactive
secondary metabolites (Figure. IV).Although not investigated in
this work, these metabolites mayplay an important ecological role
in the survival of this species.
Kalkitoxin has potent biologicalactivities which inspire us to
further investigation of its biologicalproperties and mechanism of
toxicities.Kalkitoxin also possesses a unique structurewith
relatively simple chemical charactericsand small molecular weight.
These features would be advantagesfor kalkitoxin to serve as a
lead compound in drug developmentand as biochemical probes for
the discovery of pharmacologicaland biochemical processes.
The malyngamide class represents arich family of compounds,
which offer a great deal ofinvestigative possibilities in areas such
as algal physiology,chemo-defense, chemo-communication, and
chemical ecology.These new malyngamides display very
interesting chemical features.In particular, malyngamide J
possesses a pentosering with a highly electro dense
epoxycyclohexenone ring at one end,and a lipid portion at another
end. A nitrogen-containingunit connects these two parts intothe
molecule.These features impressed usbased on our knowledge and77
experience about known drugs. Theseexciting features also
motivated us to search and develop noveland sensitive techniques
to best detect and uncovertheir full biological properties.Extract of Lyngbya majuscula from Playa Kalki, Curacao
4.32g
Gradient Vacuum Chromatography
EtOAc / Hexane 4%--100%
A B C
NS 0
kalkitoxin
12.9 mg
S
F
O 0
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Figure IV.1The Chemical Diversity of Lyngbya majusculafrom Play Kalki, Curacao.79
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